Last reviewed · How we verify
LY3022855
At a glance
| Generic name | LY3022855 |
|---|---|
| Also known as | IMC-CS4 |
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas (EARLY_PHASE1)
- A Study of LY3022855 In Participants With Breast or Prostate Cancer (PHASE1)
- A Study of IMC-CS4 in Subjects With Advanced Solid Tumors (PHASE1)
- LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma (PHASE1, PHASE2)
- A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY3022855 CI brief — competitive landscape report
- LY3022855 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI